专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009008666A2 AUTOLOGOUS DENDRITIC CELL MEDIATED BY PHOTODYNAMIC THERAPY HAVING THE ABILITY TO SUPPRESS THE GROWTH OF TUMOR 审中-公开
标题翻译：通过光动力疗法介导的自体树突状细胞具有抑制肿瘤生长的能力
公开(公告)号：WO2009008666A2
公开(公告)日：2009-01-15
申请号：PCT/KR2008/004042
申请日：2008-07-09
申请人： CREAGENE INC. , KANG, Mi-Sun , LIM, Dae-Seog , JEONG, Ju-Ah , LEE, Hyun-Soo , BAE, Yong-Soo
发明人： LIM, Dae-Seog , JEONG, Ju-Ah , LEE, Hyun-Soo , BAE, Yong-Soo
IPC分类号： C12N5/06
CPC分类号： C12N5/0639 , A61K2035/124 , C12N2501/22 , C12N2501/23 , C12N2501/24 , C12N2501/25 , C12N2502/30
摘要： The present invention relates to mature dendritic cells (DCs) having the enhanced ability to induce anti-tumor immune responses, and to a method for the preparation of the above-mentioned DCs through the procedure of pulsing immature DCs with lysates of cancer cells on which photodynamic therapy (PDT) has been conducted. The dendritic cell of this invention acquires an activity to induce anti-tumor immune responses so that it exerts a remarkable effect to suppress the growth of tumor.
摘要翻译：本发明涉及具有增强的诱导抗肿瘤免疫应答能力的成熟树突细胞（DC），并且涉及通过脉冲未成熟的程序制备上述DC的方法具有已经进行了光动力治疗（PDT）的癌细胞裂解物的DC。本发明的树突状细胞获得诱导抗肿瘤免疫应答的活性，从而发挥显着的抑制肿瘤生长的作用。

2. 发明申请

WO2003097671A1 CYTOPLASMIC TRANSDUCTION PEPTIDES AND USES THEREOF 审中-公开
标题翻译： CYTOPLASMIC TRANSDUCTION PEPTIDES及其用途
公开(公告)号：WO2003097671A1
公开(公告)日：2003-11-27
申请号：PCT/KR2003/000630
申请日：2003-03-28
申请人： CREAGENE INC. , KIM, Dae-You , OH, Hae-Keun , KIM, Chang-Hyun , KIM, Jung-Hwan , JEON, Choon-Ju , KIM, Ki-Tae , BAE, Yong-Soo , CHOI, In-Soo
发明人： KIM, Dae-You , OH, Hae-Keun , KIM, Chang-Hyun , KIM, Jung-Hwan , JEON, Choon-Ju , KIM, Ki-Tae , BAE, Yong-Soo , CHOI, In-Soo
IPC分类号： C07K7/06
摘要： The present invention relates to a cytoplasmic transduction peptide (CTP) showing transduction potential, as well as cytoplasmic remaining potential and various uses thereof. The CTP of this invention exhibits a transduction potential identical or higher than the conventional protein transduction, PTD, and a strong tendency to remain in the cytoplasm, so that it is very useful in inducing cytotoxic T lymphocytes (CTL) and a drug delivery system (DDS) targeting cytoplasm.
摘要翻译：本发明涉及显示转导电位的细胞质转导肽（CTP），以及细胞质剩余电位及其各种用途。本发明的CTP显示出与常规蛋白转导（PTD）相同或更高的转导电位，并且具有保留在细胞质中的强烈倾向，因此其在诱导细胞毒性T淋巴细胞（CTL）和药物递送系统 DDS）靶向细胞质。

3. 发明申请

WO2002087626A1 PHARMACEUTICAL COMPOSITIONS COMPRISING DENDRITIC CELLS FOR IMMUNOTHERAPY OF AUTOIMMUNE DISEASE AND TREATMENT METHODS USING THE SAME 审中-公开
标题翻译：包含自体免疫疾病免疫治疗的细胞的药物组合物和使用其的治疗方法
公开(公告)号：WO2002087626A1
公开(公告)日：2002-11-07
申请号：PCT/KR2002/000780
申请日：2002-04-26
申请人： CREAGENE INC. , SUNGAE BIOTECH INC. , BAE, Yong-Soo , JEON, Choon-Ju , LEE, Yoon , SONG, Ki-Duk , KIM, Chang-Hyun , KIM, Il-Soo , CHO, Hyun-Pil , DO, Seon-Gil , NAM, Hye-Jung , PARK, Jai-Kyung
发明人： BAE, Yong-Soo , JEON, Choon-Ju , LEE, Yoon , SONG, Ki-Duk , KIM, Chang-Hyun , KIM, Il-Soo , CHO, Hyun-Pil , DO, Seon-Gil , NAM, Hye-Jung , PARK, Jai-Kyung
IPC分类号： A61K48/00
CPC分类号： C12N5/064 , A61K2035/122 , A61K2039/5154 , C12N2501/24
摘要： The present invention relates to a pharmaceutical composition for immunotherapy of autoimmune disease, which comprises (a) a therapeutically effective dose of maturated dendritic cells and (b) a pharmaceutically acceptable carrier and a method for immunotherapy of autoimmune disease.
摘要翻译：本发明涉及用于自身免疫疾病的免疫治疗的药物组合物，其包含（a）治疗有效剂量的成熟树突状细胞和（b）药学上可接受的载体和自身免疫疾病的免疫治疗方法。

4. 发明申请

WO2009008666A3 AUTOLOGOUS DENDRITIC CELL MEDIATED BY PHOTODYNAMIC THERAPY HAVING THE ABILITY TO SUPPRESS THE GROWTH OF TUMOR 审中-公开
标题翻译：具有抑制肿瘤生长的能力的光动力治疗介导的自动细胞细胞
公开(公告)号：WO2009008666A3
公开(公告)日：2009-03-19
申请号：PCT/KR2008004042
申请日：2008-07-09
申请人： CREAGENE INC , KANG MI SUN , LIM DAE-SEOG , JEONG JU-AH , LEE HYUN-SOO , BAE YONG-SOO
发明人： LIM DAE-SEOG , JEONG JU-AH , LEE HYUN-SOO , BAE YONG-SOO
IPC分类号： C12N5/0784
CPC分类号： C12N5/0639 , A61K2035/124 , C12N2501/22 , C12N2501/23 , C12N2501/24 , C12N2501/25 , C12N2502/30
摘要： The present invention relates to mature dendritic cells (DCs) having the enhanced ability to induce anti-tumor immune responses, and to a method for the preparation of the above-mentioned DCs through the procedure of pulsing immature DCs with lysates of cancer cells on which photodynamic therapy (PDT) has been conducted. The dendritic cell of this invention acquires an activity to induce anti-tumor immune responses so that it exerts a remarkable effect to suppress the growth of tumor.
摘要翻译：本发明涉及具有增强的抗肿瘤免疫应答能力的成熟树突状细胞（DCs），以及通过以下步骤制备上述DC的方法：通过以下步骤将不成熟的DC脉冲化：癌细胞的裂解物光动力疗法（PDT）已经进行。本发明的树突细胞获得诱导抗肿瘤免疫应答的活性，从而具有显着的抑制肿瘤生长的作用。

5. 发明申请

WO2008130100A1 SEMI-MATURE DENTRITIC CELL 审中-公开
标题翻译：半成熟细胞
公开(公告)号：WO2008130100A1
公开(公告)日：2008-10-30
申请号：PCT/KR2008/001397
申请日：2008-03-12
申请人： CREAGENE INC. , KANG, Mi-Sun , LIM, Dae-Seog , JEONG, Ju-Ah , LEE, Hyun-Soo , BAE, Yong-Soo
发明人： KANG, Mi-Sun , LIM, Dae-Seog , JEONG, Ju-Ah , LEE, Hyun-Soo , BAE, Yong-Soo
IPC分类号： A61K35/14 , C12N5/00 , A61K48/00
CPC分类号： A61K39/0008 , A61K2035/122 , A61K2039/5154 , C12N5/064 , C12N2501/22 , C12N2501/25
摘要： The present invention relates to a pharmaceutical composition for treating rheumatoid arthritis, which comprises (a) a pharmaceutically effective amount of a semi-mature dendritic cell; and (b) a pharmaceutically acceptable carrier. The semi-mature dendritic cell of this invention has a safe and remarkably improved potential to treat or prevent rheumatoid arthritis through the activity of the suppression of auto-immune responses.
摘要翻译：本发明涉及一种用于治疗类风湿性关节炎的药物组合物，其包含（a）药学有效量的半成熟树突状细胞; 和（b）药学上可接受的载体。本发明的半成熟树突状细胞通过抑制自身免疫应答的活性具有安全和显着改善的治疗或预防类风湿性关节炎的潜力。

6. 发明申请

WO2006126865A1 METHOD FOR MEASURING EFFECTIVELY THE ACTIVITY OF CYTOTOXIC T LYMPHOCYTE IN HUMAN AND OUT-BRED ANIMALS 审中-公开
标题翻译：用于有效测定人和动物的细胞毒性T淋巴细胞活性的方法
公开(公告)号：WO2006126865A1
公开(公告)日：2006-11-30
申请号：PCT/KR2006/002029
申请日：2006-05-25
申请人： CREAGENE INC , JUNG, Sang Won , JEON, Choon Ju , BAE, Yong Soo
发明人： JUNG, Sang Won , JEON, Choon Ju , BAE, Yong Soo
IPC分类号： C12Q1/68
CPC分类号： G01N33/5091 , C07K7/06
摘要： The present invention relates to a method for measuring the activity of cytotoxic T lymphocytes (CTLs) , which comprises the steps of: (a) preparing peripheral blood mononuclear cells (PBMCs) from blood of an animal; (b) preparing mature dendritic cells by isolating monocytes from the PBMCs, differentiating the monocytes into dendritic cells for presenting an antigen molecule and pulsing dendritic cells with the antigen molecule to obtain the mature dendritic cells; (c) preparing the CTLs as an effector cell by stimulating the PBMCs with the mature dendritic cells to activate and amplify the CTLs; (d) preparing target cells by pulsing the PBMCs, monocytes or B cells with a cytoplasmic transduction peptide (CTP) -antigen complex generated by linking the antigen molecule of step (b) to the CTP; (e) treating the target cells with the effector cells; and (f) analyzing the lysis of the target cells. In addition, the present invention relates to a kit for measuring the activity of cytotoxic T lymphocytes.
摘要翻译：本发明涉及一种测定细胞毒性T淋巴细胞活性的方法，包括以下步骤：（a）从动物血液制备外周血单核细胞（PBMC）; （b）通过从PBMC分离单核细胞来制备成熟树突状细胞，将单核细胞分化成树突状细胞以呈递抗原分子并用抗原分子脉冲树突状细胞以获得成熟树突状细胞; （c）通过用成熟树突状细胞刺激PBMC来激活和扩增CTL来制备CTL作为效应细胞; （d）通过将步骤（b）的抗原分子与CTP连接而产生的细胞质转导肽（CTP） - 抗原复合体脉冲地培养PBMC，单核细胞或B细胞来制备靶细胞; （e）用效应细胞处理靶细胞; 和（f）分析靶细胞的裂解。此外，本发明涉及一种测定细胞毒性T淋巴细胞活性的试剂盒。

7. 发明申请

WO02087626A9 PHARMACEUTICAL COMPOSITIONS COMPRISING DENDRITIC CELLS FOR IMMUNOTHERAPY OF AUTOIMMUNE DISEASE AND TREATMENT METHODS USING THE SAME 审中-公开
标题翻译：含有树突状细胞用于免疫治疗自身免疫性疾病的药物组合物和使用该组合物的治疗方法
公开(公告)号：WO02087626A9
公开(公告)日：2002-12-27
申请号：PCT/KR0200780
申请日：2002-04-26
申请人： CREAGENE INC , SUNGAE BIOTECH INC , BAE YONG-SOO , JEON CHOON-JU , LEE YOON , SONG KI-DUK , KIM CHANG-HYUN , KIM IL-SOO , CHO HYUN-PIL , DO SEON-GIL , NAM HYE-JUNG , PARK JAI-KYUNG
发明人： BAE YONG-SOO , JEON CHOON-JU , LEE YOON , SONG KI-DUK , KIM CHANG-HYUN , KIM IL-SOO , CHO HYUN-PIL , DO SEON-GIL , NAM HYE-JUNG , PARK JAI-KYUNG
IPC分类号： A61K35/12 , A61K35/37 , A61P1/00 , A61P1/04 , A61P1/16 , A61P3/08 , A61P3/10 , A61P5/14 , A61P7/06 , A61P15/08 , A61P17/00 , A61P19/02 , A61P21/00 , A61P21/04 , A61P25/00 , A61P29/00 , A61P37/02 , A61P43/00 , C12N5/0784 , A61K48/00 , C12N5/00
CPC分类号： C12N5/064 , A61K2035/122 , A61K2039/5154 , C12N2501/24
摘要： The present invention relates to a pharmaceutical composition for immunotherapy of autoimmune disease, which comprises (a) a therapeutically effective dose of maturated dendritic cells and (b) a pharmaceutically acceptable carrier and a method for immunotherapy of autoimmune disease.
摘要翻译：本发明涉及用于自身免疫疾病免疫治疗的药物组合物，其包含（a）治疗有效剂量的成熟树突细胞和（b）药学上可接受的载体以及免疫治疗自身免疫性疾病的方法。

8. 发明申请

WO2002068582A2 PHOSPHOROTHIOATE (P=S) OLIGONUCLEOTIDES CONTAINING MODIFIED NUCLEOTIDES WITH SIX-MEMBERED AZASUGARS AND USE FOR AIDS THERAPY THEREOF 审中-公开
标题翻译：磷脂酰胆碱（P = S）含有改性核苷酸的寡核苷酸与六聚体亚硫酸钠的用途及其治疗用途
公开(公告)号：WO2002068582A2
公开(公告)日：2002-09-06
申请号：PCT/KR2002/000325
申请日：2002-02-27
申请人： DONGBU HANNONG CHEMICAL CO., LTD. , BAE, Yong-Soo , LEE, Dong-Sung , LIM, Hong , KIM, Sun-Ok , LEE, Kwangjun , JUNG, Kyeong-Eun
发明人： BAE, Yong-Soo , LEE, Dong-Sung , LIM, Hong , KIM, Sun-Ok , LEE, Kwangjun , JUNG, Kyeong-Eun
IPC分类号： C12N
CPC分类号： C12N15/113 , A61K38/00 , C12N15/1132 , C12N2310/315 , C12N2310/321 , C12N2310/323 , C12N2310/341 , C12N2310/3521
摘要： The present invention relates to a use of antisense oligonucleotides as an AIDS therapeutic agent. More precisely,the present invention relates to a novel use of antisense oligonucleotides as an AIDS therapeutic agent which include nucleotide derivatives in which five-membered ribose, a natural nucleotide sugar, is substituted with six-membered azasugar, and consisting of P=S backbone. Oligonucleotides of the present invention have low toxicity against cells and are working outside of cells to inhibit the viral attachment of HIV, with wide anti-viral activity against a broad spectrum of HIV variants. Therefore, oligonucleotides of the present invention can be used as one of effective AIDS therapeutic agent.
摘要翻译：本发明涉及反义寡核苷酸作为AIDS治疗剂的用途。更准确地说，本发明涉及反义寡核苷酸作为AIDS治疗剂的新用途，其包括核苷酸衍生物，其中五元核糖，天然核苷酸糖被六元氮杂糖取代，并由P = S骨架组成。本发明的寡核苷酸对细胞具有低毒性，并在细胞外工作以抑制HIV的病毒附着，对广泛的HIV变体具有广泛的抗病毒活性。因此，本发明的寡核苷酸可以用作有效的AIDS治疗剂之一。

9. 发明申请

WO2008143400A1 ANIMAL MODELS CARRYING TUMORS EXPRESSING HUMAN LIVER CANCER-SPECIFIC ANTIGEN AND METHOD FOR ANALYZING PREVENTION AND TREATMENT EFFICACY OF DENDRITIC CELLS-DERIVED IMMUNOTHERAPEUTICS USING THE ABOVE 审中-公开
标题翻译：携带肿瘤的动物模型表达人肝癌特异性抗原和分析预防和治疗使用上述细胞衍生的免疫球蛋白的效果的方法
公开(公告)号：WO2008143400A1
公开(公告)日：2008-11-27
申请号：PCT/KR2008/001420
申请日：2008-03-13
申请人： CREAGENE INC. , BAE, Yong-Soo , LEE, Hyun-Soo , MIN, Mi-Kyung , JEONG, Cheol-Woong , KANG, Kyu-Ho
发明人： BAE, Yong-Soo , LEE, Hyun-Soo , MIN, Mi-Kyung , JEONG, Cheol-Woong , KANG, Kyu-Ho
IPC分类号： C12Q1/00
CPC分类号： G01N33/57438 , A61K35/12 , A61K39/0011 , A61K2039/5154 , A61K2039/6075 , C07K14/4748 , C12N2799/027
摘要： The present invention relates to a method for analyzing the prevention and treatment efficacy of a dendritic cell-derived immunotherapeutic for liver cancer using an animal model carrying tumors expressing a human liver cancer-specific antigen, which comprises the steps of : (a) (a1) administering to a normal animal other than human dendritic cells to be analyzed, or (a1) administering to a normal animal other than human a cancer cell line expressing the human liver cancer-specific antigen to induce cancer in the normal animal; (b) (b1) administering to the animal the cancer cell line expressing the human liver cancer-specific antigen to induce cancer in the animal when the step (a1) is performed in the step (a), or (b1) administering to the animal with cancer dendritic cells to be analyzed when the step (a1) is performed in the step (a); and (c) determining the prevention and treatment efficacy of the dendritic cells as immunotherapeutics for liver cancer by measuring the formation or growth of cancer cells originated from the cancer cell line in the animal.
摘要翻译：本发明涉及使用携带表达人肝癌特异性抗原的肿瘤的动物模型分析来自树突状细胞的免疫治疗用于肝癌的预防和治疗功效的方法，其包括以下步骤：（a）（a1））给予除了待分析的人树突状细胞以外的正常动物，或（a1）向正常动物中的表达人肝癌特异性抗原的癌细胞系的人以外的正常动物施用癌细胞系，（b）（b1）当在步骤（a）中进行步骤（a1）时，（b1）向动物施用表达人肝癌特异性抗原的癌细胞系以在动物中诱导癌症，或（b1）当在步骤（a）中进行步骤（a1）时，分析具有癌症树突状细胞的动物; 和（c）通过测量起源于动物的癌细胞系的癌细胞的形成或生长来确定树突状细胞作为肝癌的免疫治疗剂的预防和治疗功效。

10. 发明申请

WO2008102937A1 MESENCHYMAL STEM CELL-MEDIATED AUTOLOGOUS DENDRITIC CELLS WITH INCREASED IMMUNOSUPPRESSION 审中-公开
标题翻译：间质干细胞介导的自体免疫细胞增殖免疫抑制
公开(公告)号：WO2008102937A1
公开(公告)日：2008-08-28
申请号：PCT/KR2007/003681
申请日：2007-07-31
申请人： CREAGENE INC. , LIM, Dae Seog , JEONG, Ju Ah , KANG, Mi-Sun , LEE, Hyun Soo , BAE, Yong Soo
发明人： LIM, Dae Seog , JEONG, Ju Ah , KANG, Mi-Sun , LEE, Hyun Soo , BAE, Yong Soo
IPC分类号： C12N5/06 , C12N5/08 , C12N5/00 , A61P37/02
CPC分类号： C12N5/064 , A61K2035/122 , C12N2502/1358
摘要： The present invention relates to a method for preparing dendritic cells which have an enhanced potential to suppress immune responses, dendritic cells carrying a potential to suppress immune responses, and a pharmaceutical composition comprising the dendritic cells capable of inducing immunosuppressive responses. The present dendritic cells having an enhanced potential to suppress immune responses can be utilized for treating various diseases or disorders through the suppression of immune responses. In addition, the enhanced immunotolerance potential of the dendritic cells of this invention ensures the cells to be effectively used as an immunosuppressive agent.
摘要翻译：本发明涉及一种制备树突细胞的方法，该方法具有增强的抑制免疫应答的潜力，具有抑制免疫应答潜力的树突状细胞，以及包含能诱导免疫抑制反应的树突状细胞的药物组合物。具有增强的抑制免疫应答潜力的本发明的树突状细胞可用于通过抑制免疫应答来治疗各种疾病或病症。此外，本发明的树突细胞的增强的免疫耐受潜力确保细胞被有效地用作免疫抑制剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式